The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

随着经济高速发展和工业化进程的加速, 生活方式的改变和老龄化进程的加速,
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

Since its inception in 2004, the “Clinical Practice Guidelines for the Treatment of Diabetes”
has attempted to promote evidence-based, rational, efficient and standardized clinical …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …